ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment 1/10/2025
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
community PP405 timeframe ? Could it replace current treatments ?
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
community There’s a war against finasteride and dht blockers
Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.
community UCLA scientists found a molecule — PP405 — that wakes up sleeping hair follicles and tells them, “Do your job.”
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
Related Research
6 / 6 results
research Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
This review examines androgenetic alopecia, detailing its causes and current treatments, but reports no new clinical results; the authors emphasize understanding its complexity for personalized therapy development.
research Androgenetic Alopecia: update on Etiology, Pathophysiology, Diagnosis and Treatment
In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.
research Research progress in the treatment of non-scarring alopecia: mechanism and treatment
This review reports that while current treatments for non-scarring alopecia, like minoxidil and finasteride, have limited efficacy due to side effects, natural remedies may offer more effective management with potentially fewer side effects, though their varying safety profiles call for further investigation.
research Diagnostik und Therapie der kutanen Androgenisierung im klimakterischen Übergang sowie in der Peri- und Postmenopause: Hirsutismus und Alopezie
This review discusses therapeutic principles for managing hirsutism and androgenetic alopecia during the menopausal transition and peri-/postmenopause but reports no new clinical results.
research Evaluación de la eficacia y seguridad del tratamiento tópico y del tratamiento oral en la alopecia androgenética y hormonal
This study suggests that a combination of topical minoxidil with oral finasteride and dutasteride may promote new hair growth in androgenetic alopecia, with minor safety concerns reported.
research Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.